Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Figures & data

Figure 1. Consort flow diagram.

Table 1. Characteristics of patients who developed BV-induced pulmonary toxicities.

	Case 1	Case 2	Case 3	Case 4
Age/gender	28/male	76/male	53/female	47/male
BV-induced pneumonitis classification	Likely	Likely	Likely	Possibly
Pulmonary symptoms	Dry cough, SOB, decrease in DLCO	Dry cough, hypoxic respiratory failure	Dry cough, DOE, fatigue	Persistent cough, SOB, DOE
BV indication	HL (previously untreated, stage IV)	HL (previously untreated, stage II)	ALCL (previously untreated, stage II)	ALCL (relapsed, stage IV)
Timing of symptoms relative to BV treatment	During therapy after cycle 3 of AAVD	<2 months after completion of AAVD	During therapy after cycle 2 of BV-CHP	<2 months after completion of BV
BV doses prior to pulmonary symptoms	7	6	2	21
Cumulative BV dose (mg/kg)	10.6	8.8	16.1	30.4
Smoking history	No	Yes	Yes	No
Prior pulmonary toxic agents (cumulative dose)	No	No	No	Gemcitabine (6000 mg/m^2), carmustine (525 mg/m^2)
Dose changes	Dose decrease followed by discontinuation	N/A	Discontinued	N/A
Required steroids	Yes	Yes	Yes	No
Chest X-ray	Nonsignificant	Ground glass opacities	Nonsignificant	Retrocardiac consolidation
DLCO (%)	Before BV: 89 After BV: 73	N/A	After BV: 40 With steroids: 49	N/A

Abbreviations: BV: brentuximab vedotin, SOB: shortness of breath, DLCO: diffusing capacity for carbon monoxide; DOE: dyspnea on exertion; HL: Hodgkin's lymphoma; ALCL: anaplastic large cell lymphoma; AAVD: brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; BV-CHP: brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone.